An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 2935783)

Published in Cancer Immun on March 27, 2008

Authors

Verena Voelter1, Alessia Pica, Julien Laurent, Donata Rimoldi, Hanifa Bouzourene, Ali Sajadi, Maurice Matter, Pedro Romero, Nathalie Rufer, Daniel E Speiser

Author Affiliations

1: Multidisciplinary Oncology Center, University of Lausanne Hospitals (CHUV), Lausanne, Switzerland. vvoelter@celgene.com

Articles cited by this

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res (2006) 2.68

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res (2004) 1.57

Shedding light on immunotherapy for cancer. N Engl J Med (2004) 1.54

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol (2005) 1.36

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29

Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol (2007) 1.23

A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol (2006) 1.13

Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res (2003) 0.97

Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol (2006) 0.94

An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest (2004) 0.90

CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol (2005) 0.85

Articles by these authors

The Pathway Tools software. Bioinformatics (2002) 14.89

TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86

Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol (2002) 4.50

Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59

Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28

Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 3.05

Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94

Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry (2005) 2.94

"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood (2002) 2.88

The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol (2008) 2.87

The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics (2008) 2.72

Impact of seawater acidification on pH at the tissue-skeleton interface and calcification in reef corals. Proc Natl Acad Sci U S A (2012) 2.64

Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol (2007) 2.59

Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum (2008) 2.15

Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry (2007) 1.93

EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming. J Biol Chem (2006) 1.91

Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84

Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol (2009) 1.81

Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81

Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood (2003) 1.78

Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77

D²P²: database of disordered protein predictions. Nucleic Acids Res (2012) 1.75

New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74

Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology (2005) 1.71

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.70

Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol (2002) 1.68

In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A (2007) 1.65

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63

Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A (2009) 1.61

Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer (2002) 1.60

Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58

Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun (2006) 1.58

T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol (2013) 1.57

Rational drug design via intrinsically disordered protein. Trends Biotechnol (2006) 1.57

Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 1.55

Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology (2009) 1.53

PAR2 promotes vaccine-induced protection against Helicobacter infection in mice. Gastroenterology (2011) 1.52

MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51

Improving protein order-disorder classification using charge-hydropathy plots. BMC Bioinformatics (2014) 1.50

Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48

RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood (2007) 1.47

Transcriptional profiling of Caulobacter crescentus during growth on complex and minimal media. J Bacteriol (2004) 1.46

Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis (2005) 1.45

Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med (2002) 1.44

Effect of timing of surgery on survival after preoperative hyperfractionated accelerated radiotherapy (HART) for locally advanced rectal cancer (LARC): is it a matter of days? Acta Oncol (2006) 1.43

Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene (2002) 1.42

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother (2013) 1.42

Conservation of intrinsic disorder in protein domains and families: I. A database of conserved predicted disordered regions. J Proteome Res (2006) 1.42

Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med (2003) 1.41

A cost-effective algorithm for hereditary nonpolyposis colorectal cancer detection. Am J Clin Pathol (2006) 1.40

The three main stumbling blocks for anticancer T cells. Trends Immunol (2012) 1.38

Heat shock cognate protein 70 is involved in rotavirus cell entry. J Virol (2002) 1.37

Rotavirus gene silencing by small interfering RNAs. EMBO Rep (2002) 1.36

Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33

Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods (2005) 1.33

The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol (2009) 1.32

Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol (2007) 1.32

Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res (2012) 1.30

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29

Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J Immunol (2006) 1.28